Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.
Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM. Morris ZS, et al. Among authors: loibner h. Cancer Immunol Res. 2018 Jul;6(7):825-834. doi: 10.1158/2326-6066.CIR-17-0353. Epub 2018 May 10. Cancer Immunol Res. 2018. PMID: 29748391 Free PMC article.
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM. Albertini MR, et al. Among authors: loibner h. Cancer Immunol Immunother. 2018 Oct;67(10):1647-1658. doi: 10.1007/s00262-018-2223-z. Epub 2018 Aug 3. Cancer Immunol Immunother. 2018. PMID: 30073390 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN. Siebert N, et al. Among authors: loibner h. MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19. MAbs. 2016. PMID: 26785755 Free PMC article. Clinical Trial.
Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells.
Kircheis R, Siegl P, Grunt S, Halanek N, Loibner H, Mudde GC, Nechansky A. Kircheis R, et al. Among authors: loibner h. Cancer Immunol Immunother. 2007 Jun;56(6):863-73. doi: 10.1007/s00262-006-0231-x. Epub 2006 Sep 29. Cancer Immunol Immunother. 2007. PMID: 17009044 Free PMC article.
A clinical development paradigm for cancer vaccines and related biologics.
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group. Hoos A, et al. Among authors: loibner h. J Immunother. 2007 Jan;30(1):1-15. doi: 10.1097/01.cji.0000211341.88835.ae. J Immunother. 2007. PMID: 17198079 Free article. Review.
58 results